(Disclaimer: I'm not a doctor.) It is really not fair to say that the existing stimulant drugs are addicting without clarifying that you would likely have to take several times over the amount prescribed by a doctor in order to become addicted. Certainly dependency is possible at medical doses, but that is the case for any technology that enables a person to function in ways he otherwise could not. People seem to confuse the the details of the medical use of these drugs with the recreational use, but there is a world of difference between the size of the doses taken by patients for treatment and the size of the doses taken by idiots for recreation. There is also a crucial difference between the effects sought by patients versus those sought by idiots. The patient wants just enough stimulation to keep the lights on in the left prefrontal cortex. The idiot wants to overload the dopamine receptors (or something to that effect), the problem with this being that the brain downregulates (i.e. desensitizes) the receptors and hence he needs to take ever more of the drugs until he eventually burns the receptors out or his heart explodes or something. I don't even know what the eventual result of such usage is, but I don't imagine it could be good.
P2D Bioscience aims for ADHD drug without addictive side effects
P2D Bioscience is developing nine drug candidates, but its lead candidates are intended to treat ADHD, a condition that mainly affects children and is characterized by inattention, hyperactivity and impulsivity, as the name would suggest.
CEO Frank Zemlan sees a huge potential market for an ADHD drug that treats the conditions equally as well as current drugs like Adderall and Ritalin, but doesn’t bring with it the addictive side effects.
After running off of foundation money and grants for the last few years, the company is ready to transition to private funding, Zemlan said. And P2D is looking to India for that investment.
The company, which has 12 full- and part-time employees, already has a strong Indian presence, with two executives working in the country. That’s made it easier for P2D to establish relationships with the venture capitalists and venture arms of pharmaceutical companies that Zemlan expects to fund the company’s $4 million to $5 million series A round of investment.
Zemlan tried hitting up U.S. venture capitalists, but much of that dialogue was during the recession of 2008 and 2009, so those talks “didn’t go anywhere,” he said.
“When we went to India, things started happening much more quickly,” Zemlan said. “We got a much more positive response there.”
P2D’s next steps involve clinical testing of its ADHD candidates. Zemlan puts the current market for ADHD drugs at $3.5 billion, but if the company’s drugs work like he hopes they do, that number could be headed up.
“The market will expand incredibly if we get a drug on the market that’s not addicting,” he said.
And there’s little doubt that drugs like Ritalin, the most-prescribed ADHD pharmaceutical, have the potential to be addictive. Like cocaine, Ritalin results in a rapid increase in levels of the chemical dopamine in the brain.
P2D’s drugs, on the other hand, bring a much slower release of dopamine, reducing the likelihood of addiction, according to Zemlan. “They don’t have that punch that results in the high you get with amphetamines,” he said.
As of 2007, 5.4 million U.S. children aged 4 to 17 had been diagnosed with ADHD, and about half that amount were receiving treatment for it, according to the Centers for Disease Control and Prevention. It’s probably pretty safe to say that percentage would rise if parents could choose a drug without side effects.
That’s where P2D’s lead drug candidate, PD2007, comes in. It’s important to note that the drug is several years away from approaching market approval and hasn’t been tested in humans. However, preclinical studies indicate that its efficacy is equal to Adderall and Ritalin, Zemlan said.
The company’s immediate plan, possibly aided by Indian venture capitalists, is to file an Investigational New Drug Application (IND) that, if approved by U.S. regulators, would give P2D the right to begin human testing.